Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge is advising Medivir in connection with its rights issue
Mandate

Vinge is advising Medivir in connection with its rights issue

December 14, 2020 Capital Markets and Public M&A

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is listed on Nasdaq Stockholm, Small Cap.

Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

 Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.
January 23, 2026

Vinge advises EQT AB on its combination with Coller Capital

 Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.
January 22, 2026

Vinge advises Nordic Re-Finance AB on a Swedish railway financing

Vinge has acted as Swedish legal counsel to Nordic Re-Finance AB, a leading lessor of locomotives for rail freight traffic in Scandinavia, in connection with the execution of a EUR 250m debt package fully underwritten by Natixis CIB.
January 21, 2026